Biomedical subjects

R Ariano

Publications and source records attributed to R Ariano.

40 records · Page 3Linked to original sources

PubMedDate not supplied

Monitoring of specific IgG4 antibodies in respiratory allergy due to the pollen of Parietaria judaica. Evidence for a protective role.

Two groups of 20 patients having an allergic rhinitis due to the pollen of Parietaria judaica were studied, one received a treatment of specific hyposensitization, the other one a placebo. All of them were monosensitized. The study was carried out using double blind methodology and was conducted for one year. Each case was assessed by clinical tests: case history, skin tests, score symptoms, drug consumption, nasal provocation test and by in vitro tests (FAST technique): total and specific IgGE, specific IgG4. The clinical tests revealed a statistically significant improvement in the treated group as compared to those receiving the placebo. We found a statistically significant regular and important increase of specific IgG4 values in the treated group. In this case, the specific IgG4 antibodies most likely play a protective role and act as blocking antibodies.

Allergens↗

PubMedDate not supplied

Double-blind placebo controlled specific immunotherapy with mixed Cupressaceae taxodiaceae pollens in respiratory allergy to Cupressus sempervirens.

Twenty adult patients presenting a respiratory allergy to the pollen of Cupressus sempervirens were randomly divided into two groups; one received a placebo the other one an equal mixture of Cupresssus sempervirens and Cryptomeria japonica pollen during a period of 3 years (1993-1996). According to the following criteria: symptoms score, drug consumption, skin test and RAST, nasal provocation test, the results for the treated group were statistically better than those for the placebo group. No side effects were observed.

Adult↗

PubMedDate not supplied

Late onset asthma clinical and immunological data: importance of allergy.

In people over 65 years of age (mean age 72) late onset asthma (LOA) is often mistaken for chronic obstructive pulmonary disease (COPD). Furthermore, it is generally believed that true allergic asthma starts very seldom in old age and that, in this case, it is actually intrinsic asthma i.e., without any sensitization to aeroallergens. The aim of this study was to show that LOA is not an uncommon entity and is often allergic. Among a population of 1,888 subjects (over 65 years of age) in a general medicine ward we found 21 patients (1.1%) corresponding to this entity. The diagnosis of asthma was assessed according to clinical data, pulmonary function and nasal provocation tests, and blood eosinophilia. The diagnosis of atopy was assessed on total IgE, prick tests and RAST for the commonest allergens of our area. This group of 21 patients was compared to three groups of age-matched subjects including: 68 patients afflicted with chronic bronchitis, a group of 14 patients who had asthma before the age of 65 (presenile asthma), and 20 normal controls. A group of 15 asthmatics under age 65 was also included (young asthma mean age 37). We found a rather high incidence of allergy (72%), mostly to Dermatophagoides pteronyssinus, but also to the pollens Parietaria judaica, grasses and Olea europea. Although the average age (except in the young asthma group) and the severity of symptoms were the same in the four groups, unexpectedly mean RAST and skin test values were higher in LOA than in the two groups of young asthmatics and presenile asthmatics. It was concluded that LOA is not uncommon among elderly patients over 65, which is in contrast with most previous studies; 72% of our cases were allergic, the main allergens being mite, and Parietaria judaica pollen.

Adult↗

PubMedDate not supplied

Efficacy and safety of oral immunotherapy in respiratory allergy to Parietaria judaica pollen. A double-blind study.

Two groups of 15 patients with respiratory allergy due to the pollen of Parietaria judaica were studied; one received a treatment of oral specific hyposensitization, the other one a placebo. All of them were monosensitized and clinically matched according to age, gender, score symptoms, drug consumption, skin test and RAST, and nasal or bronchial provocation test. The pollen counts were the same during this period. The study was double-blind and lasted 2 years. The clinical tests including score symptoms, drug consumption, and nasal or bronchial provocation test, revealed a statistically significant improvement in the treated group as compared to the placebo group. No side effects were observed.

Administration, Oral↗